Skip to main content
. Author manuscript; available in PMC: 2019 Feb 1.
Published in final edited form as: Biotechnol J. 2017 Oct 30;13(2):10.1002/biot.201700097. doi: 10.1002/biot.201700097

Figure 2. Schematic representation of the manufacture process of CAR-T cells used in clinical trials.

Figure 2

T cells are collected from the patient usually through leukapheresis (1) and then activated (2) and transduced with a retroviral vector (3). CAR-T cells are then expanded (4) to obtain sufficient numbers to infuse back into the patient a few days or weeks later (5).